GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clementia Pharmaceuticals Inc (NAS:CMTA) » Definitions » Total Long-Term Liabilities

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Total Long-Term Liabilities : $0.00 Mil (As of Dec. 2018)


View and export this data going back to 2017. Start your Free Trial

What is Clementia Pharmaceuticals Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Clementia Pharmaceuticals's Total Long-Term Liabilities for the quarter that ended in Dec. 2018 was $0.00 Mil.


Clementia Pharmaceuticals Total Long-Term Liabilities Historical Data

The historical data trend for Clementia Pharmaceuticals's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clementia Pharmaceuticals Total Long-Term Liabilities Chart

Clementia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18
Total Long-Term Liabilities
21.60 147.98 185.71 - -

Clementia Pharmaceuticals Quarterly Data
Dec14 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Clementia Pharmaceuticals Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Clementia Pharmaceuticals Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Clementia Pharmaceuticals's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Clementia Pharmaceuticals (Clementia Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4150 St Catherine Street West, Suite 550, Montreal, QC, CAN, H3Z 2Y5
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Headlines